ClinVar Genomic variation as it relates to human health
NM_007294.4(BRCA1):c.5152+6T>C
The aggregate germline classification for this variant, typically for a monogenic or Mendelian disorder as in the ACMG/AMP guidelines, or for response to a drug. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the aggregate classification.
Stars represent the aggregate review status, or the level of review supporting the aggregate germline classification for this VCV record. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. The number of submissions which contribute to this review status is shown in parentheses.
Pathogenic(1); Likely pathogenic(2); Uncertain significance(2)
No data submitted for somatic clinical impact
No data submitted for oncogenicity
Variant Details
- Identifiers
-
NM_007294.4(BRCA1):c.5152+6T>C
Variation ID: 125777 Accession: VCV000125777.17
- Type and length
-
single nucleotide variant, 1 bp
- Location
-
Cytogenetic: 17q21.31 17: 43063868 (GRCh38) [ NCBI UCSC ] 17: 41215885 (GRCh37) [ NCBI UCSC ]
- Timeline in ClinVar
-
First in ClinVar Help The date this variant first appeared in ClinVar with each type of classification.
Last submission Help The date of the most recent submission for each type of classification for this variant.
Last evaluated Help The most recent date that a submitter evaluated this variant for each type of classification.
Germline Apr 4, 2014 May 1, 2024 Feb 7, 2023 - HGVS
- ... more HGVS ... less HGVS
- Protein change
- -
- Other names
-
IVS18+6T>C
- Canonical SPDI
- NC_000017.11:43063867:A:G
-
Functional
consequence HelpThe effect of the variant on RNA or protein function, based on experimental evidence from submitters.
-
functionally_abnormal; Sequence Ontology [ SO:0002218]The saturation genome editing (SGE) assay for BRCA1 NM_007294.3:c.5152+6T>C, a SPLICE REGION variant, produced a function score of -1.4, corresponding to a functional classification of LOSS_OF_FUNCTION. SGE function score ranges for classification are as follows: ‘functional’, score > -0.748; ‘intermediate’, -0.748 > score > -1.328; ‘non-functional’, score < -1.328. The median synonymous SNV scored 0.0 and the median nonsense SNV scored -2.12. [submitted by Brotman Baty Institute, University of Washington]
-
Global minor allele
frequency (GMAF) HelpThe global minor allele frequency calculated by the 1000 Genomes Project. The minor allele at this location is indicated in parentheses and may be different from the allele represented by this VCV record.
- -
-
Allele frequency
Help
The frequency of the allele represented by this VCV record.
- -
- Links
Genes
Gene | OMIM | ClinGen Gene Dosage Sensitivity Curation |
Variation Viewer
Help
Links to Variation Viewer, a genome browser to view variation data from NCBI databases. |
Related variants | ||
---|---|---|---|---|---|---|
HI score
Help
The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
TS score
Help
The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
Within gene
Help
The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants. |
All
Help
The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene. |
|||
BRCA1 | Sufficient evidence for dosage pathogenicity | No evidence available |
GRCh38 GRCh37 |
13044 | 14850 |
Conditions - Germline
Condition
Help
The condition for this variant-condition (RCV) record in ClinVar. |
Classification
Help
The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions) |
Review status
Help
The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. |
Last evaluated
Help
The most recent date that a submitter evaluated this variant for the condition. |
Variation/condition record
Help
The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page. |
---|---|---|---|---|
Conflicting interpretations of pathogenicity (4) |
criteria provided, conflicting classifications
|
Aug 1, 2020 | RCV000112523.7 | |
Uncertain significance (1) |
criteria provided, single submitter
|
Jun 20, 2022 | RCV000687321.9 | |
Pathogenic/Likely pathogenic (2) |
criteria provided, multiple submitters, no conflicts
|
Feb 7, 2023 | RCV001525568.8 |
Submissions - Germline
Classification
Help
The submitted germline classification for each SCV record. (Last evaluated) |
Review status
Help
Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria) |
Condition
Help
The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
|
---|---|---|---|---|---|
Uncertain significance
(Apr 03, 2017)
|
criteria provided, single submitter
Method: clinical testing
|
Breast-ovarian cancer, familial, susceptibility to, 1
Affected status: unknown
Allele origin:
unknown
|
Counsyl
Accession: SCV000785071.2
First in ClinVar: Apr 04, 2014 Last updated: Apr 04, 2014 |
|
|
Likely pathogenic
(Aug 01, 2020)
|
criteria provided, single submitter
Method: clinical testing
|
Breast-ovarian cancer, familial, susceptibility to, 1
(Autosomal dominant inheritance)
Affected status: unknown
Allele origin:
germline
|
Kong lab, Department of Laboratory Medicine, National Cancer Center
Accession: SCV003923308.1
First in ClinVar: May 27, 2023 Last updated: May 27, 2023 |
Comment:
The c.5152+6T>C variant in BRCA1 has been detected in a PT51 patient, who was diagnosed with triple-negative breast cancer (TNBC) IDC at 39 years of … (more)
The c.5152+6T>C variant in BRCA1 has been detected in a PT51 patient, who was diagnosed with triple-negative breast cancer (TNBC) IDC at 39 years of age. BRCA1 c.5152+6T>C mRNA transcripts were abnormal compared with their corresponding wild-type transcripts (effect on RNA splicing); this variant produced a combined exon 17 and 19 by exon 18 skipping in BRCA1 and was predicted to be an in-frame deletion (26 amino acids: 1692~1717 a.a.) of the BRCA1 C-terminal (BRCT) domain of BRCA1 (Ryu 2020; PMID: 32761968). This variant does not have frequency information in genome databases, including ExAC (http://exac.broadinstitute.org/) and gnomAD (http://gnomad.broadinstitue.org), and has not been reported in the literature. Moreover, BRCA1 c.5152+6T>C was not detected in the 393 healthy female Korean controls (Ryu 2020; PMID: 32761968). By employing a saturation-genome-editing technique based on CRISPR-mediated homology-directed repair, Findlay et al suggested that BRCA1 c.5152+6T>C is a loss-of-function variant (PMID: 30209399). Thus, BRCA1 c.5152+6T>C has been classified as likely pathogenic. (less)
Age: 30-39 years
Sex: female
Ethnicity/Population group: Asia
Comment on evidence:
Exon 18 (78 bp) skipping between exon 17 and exon 19 was identified by RT-PCR and Sanger sequencing in lymphocyte-derived RNA from PT51 breast cancer … (more)
Exon 18 (78 bp) skipping between exon 17 and exon 19 was identified by RT-PCR and Sanger sequencing in lymphocyte-derived RNA from PT51 breast cancer patient. Amino acid sequences of the splice variant (c.5152+6T>C) were aligned using a reference sequence (NP_009225.1) via NCBI BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi). BRCA1 c.5152+6T>C was identified to encode a BRCA1 protein with an in-frame deletion (26 amino acids: 1692~1717a.a.) in the BRCA1 C-terminal (BRCT) domain; this may affect the function of the BRCA1 BRCT domain. (less)
Method: Analyzed RNA transcripts from patient samples to compare out-comes via in silico splicing analysis. Total RNA was extracted from peripheral blood lymphocytes using the NucleoSpin RNA Blood Kit (Macherey-Nagel) or from normal tissues using the AllPrep DNA/RNA Mini Kit (Qiagen) according to manufacturer's instructions. Using total RNA (1 μg) as template, cDNA was reverse-transcribed using the Transcriptor First Strand cDNA Synthesis Kit (Roche Life Science) or ReverTra Ace qPCR RT Master Mix (Toyobo), followed by amplification via reverse transcription PCR (RT-PCR). Transcriptional product for intronic variants in BRCA1 (c.5152+6T>C) was obtained and validated by Sanger sequencing.
|
|
Uncertain significance
(Jun 20, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Hereditary breast ovarian cancer syndrome
Affected status: unknown
Allele origin:
germline
|
Labcorp Genetics (formerly Invitae), Labcorp
Accession: SCV000814884.5
First in ClinVar: Oct 10, 2018 Last updated: Feb 14, 2024 |
Comment:
Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. ClinVar contains … (more)
Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. ClinVar contains an entry for this variant (Variation ID: 125777). This variant has not been reported in the literature in individuals affected with BRCA1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change falls in intron 17 of the BRCA1 gene. It does not directly change the encoded amino acid sequence of the BRCA1 protein. It affects a nucleotide within the consensus splice site. Experimental studies have shown that this variant affects BRCA1 function (PMID: 30209399, 32123317). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. (less)
|
|
Likely pathogenic
(Feb 07, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
Hereditary cancer-predisposing syndrome
Affected status: unknown
Allele origin:
germline
|
Color Diagnostics, LLC DBA Color Health
Accession: SCV001735726.2
First in ClinVar: Jun 19, 2021 Last updated: Feb 14, 2024 |
Comment:
This variant causes a T to C nucleotide substitution at the +6 position of intron 17 of the BRCA1 gene. Multiple splicing prediction tools indicate … (more)
This variant causes a T to C nucleotide substitution at the +6 position of intron 17 of the BRCA1 gene. Multiple splicing prediction tools indicate this variant may impair RNA splicing. RNA studies have reported that this variant causes aberrant splicing and in-frame skipping of exon 17 (exon 18 based on the BIC nomenclature) (PMID: 32123317, 32761968). The aberrant transcript is expected to result in nonfunctional protein product with p.Asp1692_Trp1718delinsGly in the BRCT1 domain of the BRCA1 protein. This variant has also been reported to result in the loss of BRCA1 protein function in a haploid cell proliferation assay (PMID: 30209399). Other nucleotide substitutions at the same position, c.5152+6T>A and c.5152+6T>G, are also reported to result in loss of BRCA1 function in the same study (PMID: 30209399). This variant has been observed in an individual with triple-negative breast cancer with family history of ovarian cancer in a second-degree relative (PMID: 32761968) and in an individual with ovarian cancer (Color internal data). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Likely Pathogenic. (less)
|
|
Pathogenic
(Dec 27, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Hereditary cancer-predisposing syndrome
Affected status: unknown
Allele origin:
germline
|
Ambry Genetics
Accession: SCV002641069.3
First in ClinVar: Nov 29, 2022 Last updated: May 01, 2024 |
Comment:
The c.5152+6T>C intronic pathogenic mutation results from a T to C substitution 6 nucleotides after coding exon 16 in the BRCA1 gene. Two functional studies … (more)
The c.5152+6T>C intronic pathogenic mutation results from a T to C substitution 6 nucleotides after coding exon 16 in the BRCA1 gene. Two functional studies have found that this nucleotide substitution is deleterious (Findlay GM et al. Nature. 2018 10;562:217-222; Wai HA et al. Genet Med. 2020 06;22:1005-1014). In silico splice site analysis predicts that this alteration will weaken the native splice donor site. A close match alteration at the same nucleotide position, BRCA1 c.5152+6T>G, demonstrated abnormal splicing in the set of samples tested (Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. (less)
|
|
Uncertain significance
(Nov 25, 2004)
|
no assertion criteria provided
Method: clinical testing
|
Breast-ovarian cancer, familial 1
Affected status: yes
Allele origin:
germline
|
Breast Cancer Information Core (BIC) (BRCA1)
Accession: SCV000145345.1
First in ClinVar: Apr 04, 2014 Last updated: Apr 04, 2014 |
Number of individuals with the variant: 1
|
|
not provided
(-)
|
no classification provided
Method: in vitro
|
Breast-ovarian cancer, familial 1
Affected status: not applicable
Allele origin:
not applicable
|
Brotman Baty Institute, University of Washington
Accession: SCV001243638.1
First in ClinVar: Apr 18, 2020 Last updated: Apr 18, 2020 |
Method: saturation genome editing in haploid cells
Result:
LOSS_OF_FUNCTION:-1.39626508303885
|
Germline Functional Evidence
Functional
Help
The functional consequence of the variant, based on experimental evidence and provided by the submitter. consequence |
Method
Help
A brief description of the method used to determine the functional consequence of the variant. A citation for the method is included, when provided by the submitter. |
Result
Help
A brief description of the result of this method for this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting functional evidence for the germline classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
---|---|---|---|---|
functionally_abnormal
|
Method citation(s):
|
|
Brotman Baty Institute, University of Washington
Accession: SCV001243638.1
|
Comment:
The saturation genome editing (SGE) assay for BRCA1 NM_007294.3:c.5152+6T>C, a SPLICE REGION variant, produced a function score of -1.4, corresponding to a functional classification of … (more)
The saturation genome editing (SGE) assay for BRCA1 NM_007294.3:c.5152+6T>C, a SPLICE REGION variant, produced a function score of -1.4, corresponding to a functional classification of LOSS_OF_FUNCTION. SGE function score ranges for classification are as follows: ‘functional’, score > -0.748; ‘intermediate’, -0.748 > score > -1.328; ‘non-functional’, score < -1.328. The median synonymous SNV scored 0.0 and the median nonsense SNV scored -2.12. (less)
|
Citations for germline classification of this variant
HelpTitle | Author | Journal | Year | Link |
---|---|---|---|---|
Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer. | Ryu JS | Cancer science | 2020 | PMID: 32761968 |
Blood RNA analysis can increase clinical diagnostic rate and resolve variants of uncertain significance. | Wai HA | Genetics in medicine : official journal of the American College of Medical Genetics | 2020 | PMID: 32123317 |
Accurate classification of BRCA1 variants with saturation genome editing. | Findlay GM | Nature | 2018 | PMID: 30209399 |
Aberrant 5' splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization. | Buratti E | Nucleic acids research | 2007 | PMID: 17576681 |
Statistical features of human exons and their flanking regions. | Zhang MQ | Human molecular genetics | 1998 | PMID: 9536098 |
https://sge.gs.washington.edu/BRCA1/ | - | - | - | - |
Text-mined citations for rs80358074 ...
HelpRecord last updated Oct 08, 2024
This date represents the last time this VCV record was updated. The update may be due to an update to one of the included submitted records (SCVs), or due to an update that ClinVar made to the variant such as adding HGVS expressions or a rs number. So this date may be different from the date of the “most recent submission” reported at the top of this page.